Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioavailability of BI 1356 and Glyburide in Healthy Male and Female Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02183428
Recruitment Status : Completed
First Posted : July 8, 2014
Last Update Posted : July 8, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
The objective of this study was to investigate the effect of multiple doses BI 1356 given once daily in the estimated highest therapeutic dose of 5 mg until steady state on the pharmacokinetics, safety, and tolerability of a single oral conventional therapeutic dose of 1.75 mg glyburide. In addition, the effect of glyburide as a single oral dose of 1.75 mg being a conventional therapeutic dose on the multiple dose pharmacokinetics of BI 1356 was investigated. Pharmacokinetic profiles of glyburide were determined when given alone or in combination with BI 1356. Pharmacokinetic profiles of BI 1356 and its inactive metabolite CD 1750 were determined at steady state of BI 1356 when given alone or in combination with glyburide.

Condition or disease Intervention/treatment Phase
Healthy Drug: BI 1356 Drug: Glyburide Drug: BI 1356 + Glyburide Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Relative Bioavailability of BI 1356 and Glyburide After Concomitant Administration of Multiple Oral Doses of BI 1356 5 mg Once Daily and a Single Oral Dose of Glyburide 1.75 mg Compared With the Bioavailability of BI 1356 and Glyburide After Each Treatment Given Alone in Healthy Male and Female Volunteers (an Open Label, Randomised, Two-way Crossover Study of Phase I)
Study Start Date : May 2008
Actual Primary Completion Date : July 2008

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BI 1356

Treatment sequence AB_C or C_AB

  • Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by
  • Treatment B: 1 day of combined treatment of BI1356 and glyburide
  • Treatment C: 1 day of treatment with glyburide alone
Drug: BI 1356
Drug: Glyburide
Drug: BI 1356 + Glyburide
Active Comparator: Glyburide

Treatment sequence AB_C or C_AB

  • Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by
  • Treatment B: 1 day of combined treatment of BI1356 and glyburide
  • Treatment C: 1 day of treatment with glyburide alone
Drug: BI 1356
Drug: Glyburide
Drug: BI 1356 + Glyburide



Primary Outcome Measures :
  1. AUC0-infinity (area under the concentration-time curve of glyburide in plasma) for several time points [ Time Frame: up to 48 hours after drug administration ]
  2. Cmax (maximum measured concentration of glyburide in plasma) for several time points [ Time Frame: up to 48 hours after drug administration ]
  3. AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ) of BI 1356 [ Time Frame: up to 48 h after drug administration ]
  4. Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ) of BI 1356 [ Time Frame: up to 48 h after drug administration ]

Secondary Outcome Measures :
  1. tmax (time from dosing to the maximum concentration of the analyte in plasma) for several time points [ Time Frame: up to 48 hours after drug administration ]
  2. λz (terminal rate constant in plasma) [ Time Frame: up to 48 hours after drug administration ]
  3. t1/2 (terminal half-life of the analyte in plasma) [ Time Frame: up to 48 hours after drug administration ]
  4. MRTpo (mean residence time of the analyte in the body after po administration) for several time points [ Time Frame: up to 48 hours after drug administration ]
  5. CL/F (apparent clearance of the analyte in the plasma after extravascular administration) for several time points [ Time Frame: up to 48 hours after drug administration ]
  6. Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose) for several time points [ Time Frame: up to 48 hours after drug administration ]
  7. Number of patients with adverse events [ Time Frame: up to 11 weeks ]
  8. Assessment of tolerability by investigator on a 4-point scale [ Time Frame: Day 1 of treatment B, day 3 of treatment B and C ]
  9. AUC (area under the concentration-time curve of the analyte in plasma) for several time points [ Time Frame: up to 48 h after drug administration ]
  10. Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ) of CD 1750 [ Time Frame: up to 48 h after drug administration ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy females and males according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead (ECG) Electrocardiogram, clinical laboratory tests
  • Age ≥18 and Age ≤55 years
  • BMI ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index)
  • Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation

Exclusion Criteria:

  • Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
  • Any evidence of a clinically relevant concomitant disease
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Surgery of the gastrointestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of relevant orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of relevant allergy or hypersensitivity (including allergy to drug or its excipients)
  • Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  • Use of drugs which might reasonably influence the results of the trial or that prolong the QT/QTc interval based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial, including herbal products
  • Participation in another trial with an investigational drug within two months prior to administration or during the trial
  • Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
  • Inability to refrain from smoking on trial days
  • Alcohol abuse (more than 60 g/day)
  • Drug abuse
  • Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
  • Excessive physical activities (within one week prior to administration or during the trial)
  • Any laboratory value outside the reference range that is of clinical relevance
  • Inability to comply with dietary regimen of trial site
  • A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms)
  • A history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalaemia, family history of Long QT Syndrome)
  • Galactose intolerance
  • Lactase deficiency
  • Glucose-galactose-malabsorption

For all female subjects:

  • Pregnancy or planning to become pregnant within 2 months of study completion
  • Positive pregnancy test
  • No adequate contraception e.g. , sterilisation, IUD (intrauterine device), have not been using a barrier method of contraception for at least 3 months prior to participation in the study
  • Not willing or unable to use a reliable method of barrier contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during and up to 2 months after completion/termination of the trial
  • Partner is unwilling to use condoms
  • Lactation period

Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02183428    
Other Study ID Numbers: 1218.30
First Posted: July 8, 2014    Key Record Dates
Last Update Posted: July 8, 2014
Last Verified: July 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Glyburide
Linagliptin
Hypoglycemic Agents
Physiological Effects of Drugs
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action